Elziverine
Code | Size | Price |
---|
TAR-T68064-1mg | 1mg | £295.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68064-5mg | 5mg | £624.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68064-10mg | 10mg | £860.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68064-25mg | 25mg | £1,243.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68064-50mg | 50mg | £1,653.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T68064-100mg | 100mg | £2,199.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
Elziverine is an orally available small molecule calmodulin antagonist.Elziverine in vitro treatment inhibited Ca-loading-induced acanthocyte formation in SHRSP, WKY, and Wistar rats in a concentration-dependent manner.Elziverine can be used for the treatment of neurological disorders, and may be used for the study of cognitive disorders.
CAS:
95520-81-3
Molecular Weight:
543.65
Pathway:
Neuroscience
Purity:
0.9843
SMILES:
N=1C=C(C=2C=C(OC)C(OC)=CC2C1CC3=CC=C(OC)C(OC)=C3)CN4CCN(C=5C=CC=CC5OC)CC4
Target:
CaMK
References
Izu M, et al. Investigation of hepatic energy metabolism in normothermic hepatic ischemia-the effect of calmodulin antagonist on normal and cirrhotic rat liver. 1991.